Xtant Medical (NYSEAMERICAN:XTNT) Price Target Lowered to $1.00 at BTIG Research

Xtant Medical (NYSEAMERICAN:XTNT) had its target price dropped by analysts at BTIG Research from $1.50 to $1.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the medical device company’s stock. BTIG Research’s price target would suggest a potential upside of 76.96% from the company’s previous close.

Separately, Craig Hallum reiterated a “buy” rating on shares of Xtant Medical in a research report on Wednesday, March 18th. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $1.00.

Xtant Medical Price Performance

Xtant Medical stock traded up $0.02 during trading on Tuesday, reaching $0.57. The company had a trading volume of 65,571 shares, compared to its average volume of 153,923. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.06 and a current ratio of 2.21. The firm’s 50-day simple moving average is $0.60 and its 200 day simple moving average is $0.67. The firm has a market capitalization of $79.11 million, a PE ratio of 56.57 and a beta of -0.30. Xtant Medical has a 1-year low of $0.34 and a 1-year high of $0.95.

Hedge Funds Weigh In On Xtant Medical

Several institutional investors and hedge funds have recently bought and sold shares of the company. Jane Street Group LLC acquired a new stake in shares of Xtant Medical during the 2nd quarter worth approximately $26,000. Tradition Wealth Management LLC acquired a new stake in Xtant Medical during the fourth quarter worth $79,000. Wiregrass Investment Management LLC purchased a new stake in Xtant Medical in the fourth quarter valued at $81,000. Mink Brook Asset Management LLC lifted its stake in shares of Xtant Medical by 125.8% in the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after purchasing an additional 60,997 shares during the last quarter. Finally, Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Xtant Medical during the 4th quarter worth $220,000. 69.33% of the stock is currently owned by institutional investors and hedge funds.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.